Sex hormone levels in the serum of patients with pancreatic adenocarcinoma

Hormone and Metabolic Research

Volumn 29, Issue 3, 1997, Pages 115-118

  Fyssas, I ^a   Syrigos, K N ^a,b   Konstandoulakis, M M ^a   Papadopoulos, S ^a   Milingos, N ^a   Anapliotou, M ^c   Waxman, J ^b   Golematis, B C ^a  

^a HIPPOKRATION HOSPITAL   (Greece)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c LAIKO GENERAL HOSPITAL   (Greece)

Author keywords

D4 androstenedione; follicule stimulating hormone; luteinising hormone; oestradiol; pancre atic cancer; progesterone; testosterone

Indexed keywords

ANDROSTENEDIONE; ESTRADIOL; FOLLITROPIN; LUTEINIZING HORMONE; PROGESTERONE; TESTOSTERONE;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MALE; PANCREAS ADENOCARCINOMA; PANCREATITIS; PRIORITY JOURNAL; SEX DIFFERENCE;

EID: 0030986662     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-979002     Document Type: Article

References (28)

1. Williamson RCN: Pancreatic cancer: the greatest oncological challenge. Br Med J 296: 445-446 (1988).
2. Douglas RW, Wortersen R, Jansen J: Influence of cholecystokinin antagonist on the effects of cholecystokinin and bombesin on azaserine induced lesions of rat pancreas. Gastroenterology 96: 462-462 (1989).
3. Townsend CM, Franklin RB, Watson LC: Stimulation of pancreatic cancer growth by caerulein and secretin. Surg Forum 32: 228-230 (1981).
4. Poston GJ, Townsend CM, Rajaraman S: Effect of somatostatin and tamoxifen on the growth of human pancreatic cancers in nude mice. Pancreas 5: 151-157 (1990).
5. Klijn JGM, Hoff AM, Planting A, Vrweij J, Kok T, Lamberts S, Portengen H, Foekens JA: Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects. Br J Cancer 62: 627-630 (1990).
6. Perilli D, Mansi C, Savarino V, Celle G: Hormonal therapy of pancreatic carcinoma. Int J Pancretol 13: 159-168 (1993).
7. Bourhis J, Lacaine R, Augusy M, Huguier M: Protective effect of oestrogen in pancreatic cancer. Lancet ii: 977 (1987).
8. Andren-Sandberg A: Steroid receptors in pancreatic cancer, a review. In: Preece PE, Cuschieri A, Rosin RD (eds), Cancer of the Bile Ducts and Pancreas. Saunders, Philadelphia (1989), pp 175-187.
9. Andren-Sandberg A: Androgen influence on exocrine pancreatic cancer. Int J Pancreatol 4: 363-369 (1989b).
10. Andren-Sandberg A, Kirdani RY: Oestrogen binding protein in pancreatic cancer. In: Preece PL, Cuschieri A, Rosin RD (eds), Cancer of the Bile. Ducts and Pancreas. WB Saunders Co, Philadelphia (1989), pp 175-188.
11. Andren-Sandberg A, Borg A, Dawiskiba S, Ihse I, Ferno M: Estrogen receptors and estrogen-binding protein in pancreatic cancer. Digestion 25: 12-15 (1982).
12. Longnecker DS: Hormones and pancreatic cancer. Int J Pancreatol 9: 81-86 (1991).
13. Longnecker DS, Jamieson JD, Asch H: Regulation of growth and differentiation in pancreatic cancer. Pancreas 4: 256-275 (1989).
14. Redding TW, Schally A: Inhibition of growth of pancreatic carcinoma in animal models by analogues of hypothalamic hormones. Proc Natl Acad Sci USA 81: 248-252 (1984).
15. Greenway BA, Iqbal MJ, Johnson Pl, Williams R: Oestrogen receptor proteins in malignant and fetal pancreas. Br Med J 283: 751-753 (1981).
16. Greenway BA, Iqbal MJ, Johnson Pl, Williams R: Low serum testosterone concentrations in patients with carcinoma of the pancreas. Br Med J 286: 93-94 (1983).
17. Militello C, Sperti C, Foreita C, Pasquali C, Bonadimani B, Pedrozzali S: Plasma levels of testosterone and hypophyseal gonadotropins in men affected by pancreatic cancer. Digestion 30: 106 (1984).
18. Kloppel G, Maillet B: Classification and staging of pancreatic nonendocrine tumours. Radiol Clin North Am 27: 105-112 (1989).
19. Andren-Sandberg A, Rosenthal HE: Steroid receptors in exocrine glands: the pancreas and the prostate. J Steroid Biochem 11: 293 (1979).
20. Shearer MG, Taggart D, Gray C, Imrie C: Useful differentiation between pancreatic carcinoma and chronic pancreatitis by testosterone assay [Abstract]. Digestion 30: 122 (1984).
21. Corbishley TP, Iqbal M, Wilkinson M, Williams R: Circulating sex steroids and sex hormone binding globulin in pancreatic adenocarcinoma. Anticancer Res 5: 219-222 (1986).
22. Andren-Sandberg A, Backman PL: Sex hormones and pancreatic cancer. Baill Blin Gastroent 4: 941-952 (1990).
23. Corbishley TP, Iqbal MJ, Johnson PJ, Williams R: Progesterone receptors in malignant and fetal pancreatic tissue. IRCS Med Sci 12: 575 (1984).
24. Pettersen A, Lea O, Bakkevold K, Arnesjo B: Progress in pancreatic oestrogen receptors. Eur J Surg Oncol 12: 321-324 (1986).
25. Boctor AM, Band P, Grossman A: Analysis of binding of estradiol to the cytosol fraction of rat pancreas: comparison with sites in the cytosol of uterus. Endocrinology 113: 453-462 (1983).
26. Drury RE, Sandberg A: Biochemical properties and binding parameters of the pancreatic estradiol binder. Pancreas 2: 510-517 (1987).
27. Bhatavdekar JM, Patel DD, Chihlikar PR, Mehta RH, Vora HH, Karelia NH, Ghosh N, Shah NG, Neema JP: Levels of circulating peptide and steroid hormones in men with lung cancer. Neoplasma 41: 101-103 (1994).
28. Aasebo U, Bremnes RM, Aakvaag A, Slordal L: Gonadal endocrine dysfunction in patients with lung cancer: relation to responsiveness to chemotherapy, respiratory function and performance status. J Steroid Biochem Mol Biol 39: 375-380 (1991).